Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin in Intermediate Risk AML
NCT00860639Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Oct 2007
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Started Oct 2007; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00860639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00860639.